Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand

Area of Science:

• Oncology
• Nuclear Medicine
• Radiotherapy

Background:

• Targeted alpha therapy (TAT) is an emerging cancer treatment modality.
• Alpha emitters offer unique advantages over conventional therapies due to their short range and high energy deposition.
• TAT demonstrates potential for treating cancers resistant to traditional treatments.

Purpose of the Study:

• To review recent clinical experiences with targeted alpha therapy using specific alpha emitters.
• To highlight the therapeutic efficacy and potential of TAT in cancer treatment.
• To address the need for increased production of alpha emitters to meet future clinical demand.

Main Methods:

• Review of recent clinical data on targeted alpha therapy.
• Focus on clinical experience with Bismuth-213 (213Bi) and Actinium-225 (225Ac).
• Discussion of production methods for alpha emitters.

Main Results:

• Alpha radiation's short range (<0.1 mm) enables selective cancer cell killing.
• High linear energy transfer of alpha particles ensures effective cell kill, overcoming resistance.
• Recent clinical results underscore the significant therapeutic potential of TAT.

Conclusions:

• Targeted alpha therapy shows remarkable efficacy for various cancers.
• Increased production of alpha emitters is crucial for widespread clinical application.
• Alternative production methods are being explored to meet future demand for TAT agents.